In 1933, a Swiss herpetologist named Robert Mertens described a striking green pit viper from the lowland forests of Southeast Asia. The Temple Viper — Tropidolaemus wagleri — earned its name from the Buddhist temples where it coiled among incense offerings. Its venom was never the deadliest in the snake world. But it did something peculiar: it paralyzed prey by shutting down muscle signaling at the synapse, not by destroying tissue. Seventy years later, cosmetic chemists at Pentapharm isolated the active peptide responsible for that effect. They called it Waglerin-1. Then they built a synthetic mimic that could do the same thing — gently, reversibly — on the muscles that create expression lines on your face. That molecule became Syn-Ake.
Syn-Ake — its full INCI name is dipeptide diaminobutyroyl benzylamide diacetate — belongs to a category of skincare actives called neurotransmitter-inhibiting peptides. This is the same functional class as the more famous Argireline and Snap-8. But Syn-Ake takes a completely different route to relaxation. And that difference matters a lot for how it behaves on skin.
The Science Behind Neurotransmitter-Inhibiting Peptides
Every time you furrow your brow or squint into sunlight, a chain of events fires inside your facial muscles. A motor neuron releases acetylcholine into the synaptic cleft — the tiny gap between nerve ending and muscle fiber. Acetylcholine docks onto nicotinic receptors on the muscle cell surface. That binding opens ion channels. Sodium floods in. The muscle contracts. This is the neuromuscular junction at work, and it runs the same way in your forehead as it does in your biceps.
There are two ways to interrupt this cascade with a topical peptide. The first way — the Argireline approach — targets the SNARE protein complex inside the nerve terminal. SNARE proteins are the molecular machinery that fuse acetylcholine-filled vesicles to the nerve membrane for release. Argireline, a hexapeptide that mimics a fragment of SNAP-25, competes for a spot in that fusion complex. Snap-8, an octapeptide, does the same thing with a longer sequence and marginally better affinity. The result: fewer vesicles fuse, less acetylcholine is released, and the muscle receives a weaker contraction signal.
The second way — the Syn-Ake approach — skips the nerve entirely. Syn-Ake doesn’t care about SNARE proteins or vesicle fusion. It goes straight to the muscle cell and blocks the nicotinic acetylcholine receptor itself. This is receptor-level antagonism, not presynaptic inhibition. The nerve still fires. Acetylcholine still gets released. But the lock has been changed. The key no longer fits.
This mechanistic difference has real practical consequences. Because Syn-Ake acts on the muscle side of the synapse rather than the nerve side, its effects tend to be more localized and less prone to the diffusion-related unevenness that can occur with SNARE-targeting peptides. It also means Syn-Ake and Argireline can theoretically work together — they hit different parts of the same signaling chain.
Syn-Ake’s Molecular Mechanism: The Waglerin Connection
Waglerin-1, the natural peptide from Temple Viper venom, is a 22-amino-acid polypeptide with an unusual structure. It contains a “three-finger” toxin fold — a motif more commonly associated with snake neurotoxins that target postsynaptic receptors. Waglerin-1 binds specifically to the epsilon subunit of the adult muscle nicotinic acetylcholine receptor. This subunit selectivity is rare among natural toxins and is the reason Waglerin-1 is more potent against mature muscle fibers than against fetal or denervated ones.
Syn-Ake is not Waglerin-1. It is a much smaller synthetic tripeptide — beta-alanine, proline, and diaminobutyroyl benzylamide — designed to mimic the receptor-binding pharmacophore of the natural toxin without the full 22-amino-acid scaffold. The benzylamide group at the C-terminus is the key structural feature. Molecular docking studies by Gok and colleagues at Yildiz Technical University, published in the Journal of Biomolecular Structure and Dynamics in 2024, showed that Syn-Ake achieves this binding through a combination of hydrophobic interactions with the receptor pocket and hydrogen bonds with key residues in the binding site.
The result: Syn-Ake sits in the acetylcholine binding pocket of the muscle nicotinic receptor and physically prevents acetylcholine from docking. The receptor doesn’t open. Sodium doesn’t rush in. The muscle stays relaxed. Critically, because Syn-Ake is a competitive antagonist rather than an irreversible blocker, the effect wears off as the peptide diffuses away. A topical application doesn’t produce a frozen face — it produces a gentle relaxation that softens expression lines without eliminating expression.
What the Lab Data Shows
The Gok et al. 2024 study went beyond docking simulations. The team ran fifty-nanosecond molecular dynamics simulations to test whether Syn-Ake stays put once it binds. The peptide remained stable in the active sites of both MMP-13 and SIRT1 receptors for the full simulation window. This is a good sign — a peptide that wobbles out of its binding pocket after a few picoseconds isn’t a drug candidate. One that stays anchored for fifty nanoseconds of simulated time has a realistic shot at meaningful receptor occupancy.
But the study produced another finding that most Syn-Ake marketing overlooks: the peptide also showed affinity for matrix metalloproteinases, particularly MMP-13, MMP-8, and MMP-1 in decreasing order of binding energy. MMPs are enzymes that degrade collagen and elastin in the dermal matrix. The fact that Syn-Ake docked well with MMP-13 — the collagenase most strongly associated with photoaging-related collagen breakdown — suggests a second mechanism. Beyond muscle relaxation, Syn-Ake might protect the extracellular matrix from enzymatic degradation. This is speculative based on in silico data alone. No clinical study has yet confirmed MMP inhibition by Syn-Ake on living skin. But the docking scores were strong enough to justify further investigation.
The same study tested Syn-Ake’s antioxidant capacity using the DPPH radical scavenging assay. The peptide showed concentration-dependent free radical quenching. And safety testing — both MTT cytotoxicity and Ames genotoxicity assays — cleared Syn-Ake as non-toxic and non-mutagenic at cosmetic-relevant concentrations. The safe dose window was wide.
Clinical Evidence: Does It Work on Real Skin?
Here’s where the story gets both more encouraging and more nuanced. The strongest clinical data for Syn-Ake comes from a 2026 L’Oréal study published in the International Journal of Cosmetic Science by Zhu and colleagues. The research team tested a serum containing Syn-Ake alongside acetyl hexapeptide-8 — that’s Argireline — plus gluconolactone, niacinamide, and laminaria extract. This was a combination product, not a Syn-Ake monotherapy. That’s important context. We can’t attribute every result to Syn-Ake alone.
But the numbers are hard to ignore. In clinical study one, fifty participants applied the serum and had their static wrinkles assessed at multiple time points. The mean clinical scoring improvement ranged from thirty-five percent to sixty-nine percent for different wrinkle types after twelve weeks — all statistically significant at p less than zero point zero zero one. Static wrinkles started improving within the first week. That’s fast for a topical cosmetic.
Clinical study two focused on dynamic wrinkles — the ones that appear during facial movement — in forty-two participants. Improvement was more modest here: ten to thirteen percent after twelve weeks. This makes mechanistic sense. Syn-Ake’s receptor-level antagonism should affect both static and dynamic wrinkles, but dynamic lines are expression-driven and harder to suppress with a topical. Even injectable botulinum toxin takes a few days to fully silence dynamic wrinkles. A ten percent improvement from a topical serum is actually quite good.
Beyond wrinkles, the serum produced significant improvements across multiple skin quality parameters: smoothness up thirty percent, radiance up twenty-seven percent, pore appearance improved forty-three percent, elasticity up thirty-three percent, and firmness up thirty-six percent. These numbers hint that the benefits of Syn-Ake — especially in combination with niacinamide and gluconolactone — extend well beyond muscle relaxation.
The ex vivo arm of the study provided biomarker data to back up the clinical observations. Skin samples treated with the serum showed increased levels of collagen types one, three, four, and seventeen. Elastic fiber content went up. Matrix metalloproteinase-1 — the enzyme that chews through collagen — went down. This mirrors the MMP-binding prediction from the Gok in silico study and adds biological plausibility to the dual-mechanism hypothesis.
The Delivery Problem: Getting Peptides Through the Skin Barrier
All of this mechanism and clinical data means nothing if the peptide can’t reach the dermal-epidermal junction where muscles and fibroblasts live. The stratum corneum — the outermost layer of dead skin cells embedded in a lipid matrix — is a formidable barrier to anything larger than about five hundred Daltons. Syn-Ake has a molecular weight in the mid-three-hundreds by most estimates, which puts it in a favorable size range for passive diffusion. But size isn’t everything. Charge, hydrophilicity, and the peptide’s tendency to form transient aggregates all affect penetration.
This is where formulation science separates effective products from well-marketed water. A 2024 study by Hou and colleagues at Beijing Youngen Biotechnology, published in ACS Applied Bio Materials, demonstrated a novel approach using plant-derived exosomes as peptide carriers. Their NanoGlow system encapsulated acetyl hexapeptide-8 — Argireline, not Syn-Ake, but pharmacokinetically comparable — into engineered nanoscale vesicles extracted from plant cells. The exosome carriers delivered the peptide to the dermis at rates that outperformed free peptide by a significant margin. In vivo tissue slice imaging confirmed dermal deposition. This kind of delivery innovation is exactly what neurotransmitter-inhibiting peptides need. Without a competent delivery system, even the best-designed peptide stops at the stratum corneum and never meets a receptor.
For the formulator, the practical takeaways are clear. Syn-Ake needs to be paired with penetration enhancers — glycols, ethoxydiglycol, or liposomal encapsulation systems. The L’Oréal serum in the clinical study included gluconolactone, a polyhydroxy acid that doubles as a gentle exfoliant and penetration facilitator. That was almost certainly not a coincidence. The best Syn-Ake serum isn’t necessarily the one with the highest peptide concentration. It’s the one that actually delivers the peptide past the barrier.
Expert Insight: What Experienced Formulators Know
The first trap with neurotransmitter-inhibiting peptides is confusing mechanism with magnitude. A peptide that blocks nicotinic receptors in a docking simulation at minus nine point three kilocalories per mole is not a topical Botox replacement. Botulinum toxin type A cleaves SNARE proteins enzymatically — a single molecule of the toxin can disable a nerve terminal for months. Syn-Ake competes reversibly with acetylcholine. It gets displaced when acetylcholine concentrations rise. The effect is real, but it’s gentler by design. Expecting Botox-level results from a topical peptide is a category error that leads to consumer disappointment and product returns.
The second trap is pH. Syn-Ake, like most synthetic peptides, has an optimal stability window. The benzylamide moiety is susceptible to hydrolysis under strongly acidic or alkaline conditions. A serum formulated at pH three to four — common for products heavy on AHAs — will slowly degrade Syn-Ake over the shelf life. The degradation products don’t relax muscles. They just sit there. Formulators targeting the four-point-five to six-point-zero pH range will get dramatically better long-term stability. Few brands advertise their formulation pH openly. But a Syn-Ake serum that smells vinegary after three months on the shelf has probably lost most of its active.
The third trap is concentration honesty. The L’Oréal study used a multi-active serum. Most standalone Syn-Ake serums on the market don’t disclose peptide concentration — partly because the effective range is narrow. Too little and the receptor occupancy is negligible. Too much and you risk receptor desensitization, where the muscle cell downregulates receptor expression in response to chronic antagonism. This is a theoretical concern for topical peptides — no published study has documented it — but it’s a well-known phenomenon in pharmacology that experienced formulators account for. The sweet spot appears to be in the low single-digit percentage range, though precise numbers are proprietary.
Where Syn-Ake Fits in Your Routine
Syn-Ake makes the most sense as a targeted treatment, not an all-over face serum. Apply it to the areas where muscle contraction creates the deepest lines — the “eleven” furrow between the eyebrows, crow’s feet at the orbital corners, horizontal forehead lines. These are the same injection sites as botulinum toxin, and for the same anatomical reason: they’re powered by thin, superficial muscles that a topical peptide can feasibly reach from the skin surface.
Compared to Argireline, Syn-Ake offers a different mechanism — postsynaptic receptor blockade versus presynaptic SNARE inhibition. This means they pair well. A morning serum with Argireline and an evening treatment with Syn-Ake hits both sides of the neuromuscular junction. Snap-8 has the longest peptide sequence of the three and may offer marginally better SNARE inhibition than Argireline, but its mechanism is the same class. Syn-Ake remains the only commercially available topical peptide that targets the muscle receptor directly.
One practical note: Syn-Ake works on dynamic expression — the kind generated by repetitive muscle movement. It won’t do much for gravitational sagging, volume loss, or photoaging-related textural changes on its own. The L’Oréal study’s skin quality improvements almost certainly came from the niacinamide and gluconolactone, not the peptide. If your main concerns are laxity, dullness, or deep static creases that are there even when your face is at rest, pair Syn-Ake with a signaling peptide like Matrixyl or a collagen-stimulating ingredient like retinoids. Syn-Ake handles the muscle side. Let other actives handle the matrix side.
Further Reading
- Snap-8: How an 8-Amino-Acid Peptide Competes with Botox at the SNARE Complex
- Palmitoyl Tripeptide-1: Collagen Signaling Without Copper
- Matrikines: Your Skin’s Built-In Blueprint for Collagen Repair
Last reviewed: August 2026. Peptide Proof Editorial Team.
Sources
Zhu M, He X, Zhu Z, et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. International Journal of Cosmetic Science. 2026 volume 48. DOI: 10.1111/ics.70087.
Gok B, Budama-Kilinc Y, Kecel-Gunduz S. Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests. Journal of Biomolecular Structure and Dynamics. 2024 volume 42 issue 10 pages 5015 to 5029. DOI: 10.1080/07391102.2023.2223681.
Chan LKW, Lee KWA, Lee CH, et al. Cosmeceuticals in photoaging: A review. Skin Research and Technology. 2024 volume 30 issue 9. DOI: 10.1111/srt.13730.
Hou J, Wei W, Geng Z, et al. Developing Plant Exosomes as an Advanced Delivery System for Cosmetic Peptide. ACS Applied Bio Materials. 2024 volume 7 issue 5 pages 3050 to 3060. DOI: 10.1021/acsabm.4c00096.
Olsson SE, Sreepad B, Lee T, Fasih M, Fijany A. Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. JMIR Dermatology. 2024 volume 7. DOI: 10.2196/54217.
